EMA Positive on GSK-Vir Bio Sotrovimab For Early Covid

 Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –

– EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization –

– Discussions with global regulators regarding authorizations in additional countries continue to advance –

https://finance.yahoo.com/news/correction-ema-issues-positive-scientific-132600358.html